Shandong Boan Biotech licenses U.S. rights to dulaglutide biosimilar BA5101 to partner

  • Shandong Boan Biotechnology entered a U.S. licensing deal with a partner for BA5101, its dulaglutide injection biosimilar to Eli Lilly’s Trulicity.
  • The partner will handle U.S. commercialization, including filing the biologics license application, sales.
  • Boan will receive an upfront payment, milestone payments, sales-based commissions.
  • BA5101 won China marketing clearance in August 2025, positioned as the first approved Trulicity biosimilar globally.
  • 2025 Trulicity sales totaled USD 4.28 billion globally, including USD 2.91 billion in the U.S.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260611-12199926), on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.